| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KCNE1 |
| Uniprot No | P15382 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-105aa |
| 活性数据 | MILSNTTAVTPFLTKLWQETVQQGGNMSGLAHRSPRSGDGKLEALYVLMVLGFFGFFTLGIMLSYIRSKKLEHSNDPFNVYIESDAWQEKDKAYVQARVLESYRS |
| 分子量 | 37.29 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人KCNE1蛋白的模拟参考文献示例(仅供参考，实际文献需通过学术数据库核实)：
---
1. **文献名称**: *Structural Insights into KCNE1 Modulation of the KCNQ1 Potassium Channel*
**作者**: Wang, Y. et al.
**摘要**: 研究利用重组人KCNE1蛋白与KCNQ1共表达系统，通过冷冻电镜解析了二者复合物的三维结构，揭示了KCNE1如何通过跨膜螺旋调控KCNQ1通道门控动力学的分子机制。
2. **文献名称**: *Functional Characterization of a Novel KCNE1 Mutation Associated with Long QT Syndrome*
**作者**: Smith, J.L. & Kass, R.S.
**摘要**: 通过重组表达携带LQT相关突变的人KCNE1蛋白，发现该突变破坏了其与KCNQ1的相互作用，导致心脏延迟整流钾电流(Iks)减少，揭示了突变致心律失常的分子基础。
3. **文献名称**: *High-Yield Recombinant Expression and Purification of Human KCNE1 in E. coli*
**作者**: Chen, X. et al.
**摘要**: 报道了一种高效的大肠杆菌表达系统，用于重组人KCNE1蛋白的可溶性表达与纯化，为后续体外药物筛选及结构研究提供了可靠方法学支持。
4. **文献名称**: *KCNE1 Regulates Drug Sensitivity in Cancer Cells via Modulation of Potassium Channels*
**作者**: Zhang, H. & Cui, J.
**摘要**: 研究利用重组KCNE1蛋白，发现其过表达通过调控钾通道活性影响肿瘤细胞对化疗药物的敏感性，提示KCNE1可能作为癌症治疗的潜在靶点。
---
**注意**：以上内容为模拟生成，非真实存在的文献。建议通过PubMed、Google Scholar等平台检索关键词“recombinant human KCNE1”“KCNQ1/KCNE1 complex”等获取真实文献。
KCNE1 is a small transmembrane protein belonging to the KCNE family, known for regulating voltage-gated potassium (Kv) channels. It functions as an auxiliary subunit that modulates the activity of the KCNQ1 α-subunit, forming the slowly activating delayed rectifier potassium channel (I_Ks). This channel plays a critical role in cardiac action potential repolarization, ensuring proper heart rhythm. Mutations in KCNE1 are linked to congenital long QT syndrome (LQTS) and atrial fibrillation, highlighting its clinical significance.
Recombinant human KCNE1 protein is produced using biotechnological systems (e.g., E. coli or mammalian cell cultures) to enable functional studies. Its recombinant form retains structural and functional properties, allowing researchers to investigate channel assembly, gating mechanisms, and drug interactions in vitro. This protein is essential for characterizing pathogenic variants, screening potential therapeutics targeting cardiac arrhythmias, and understanding Kv channel biology. Additionally, recombinant KCNE1 aids in structural studies, such as cryo-EM or X-ray crystallography, to resolve molecular interactions within the KCNQ1-KCNE1 complex. Its applications extend to drug safety assessments, as unintended modulation of I_Ks can cause life-threatening side effects. By providing a purified, standardized tool, recombinant KCNE1 accelerates research into channelopathies and cardiovascular drug development.
×
